GlassScriptPhysician profile
Shen-Han Lin
NPI 1225230154
$11,035.23
in general payments reported to CMS, 2019-2025
28 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $705 · 2021: $1,657 · 2022: $1,981 · 2023: $1,999 · 2024: $1,973 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,994.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,518.79 | 2019-2025 | Vemlidy |
| Abbvie INC. | $1,652.73 | 2020-2025 | |
| Amgen INC. | $1,252.89 | 2020-2025 | Repatha, Evenity, Repatha |
| Novo Nordisk INC | $861.29 | 2021-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $847.90 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $464.49 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.74 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $424.22 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $409.15 | 2022-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $363.55 | 2021-2025 | Gardasil 9, Gardasil, Capvaxive |
| Madrigal Pharmaceuticals | $270.89 | 2025 | Rezdiffra |
| Biohaven Pharmaceutical Holding Company LTD. | $248.67 | 2022 | |
| Glaxosmithkline, LLC. | $207.52 | 2022-2024 | Shingrix, Arexvy |
| Pfizer INC. | $195.52 | 2023-2024 | |
| Stryker Corporation | $147.94 | 2024 | Mako |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $116.06 | 2024-2025 | Ibsrela |
| Phadia US INC. | $103.68 | 2019 | |
| Astellas Pharma US INC | $85.06 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $84.43 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $81.09 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $71.25 | 2024 | |
| Esperion Therapeutics, INC. | $47.15 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $39.96 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $34.76 | 2024-2025 | Zoryve |
| Baxter Healthcare | $24.58 | 2024 | Hillrom - Connex Spot Monitor |
| Idorsia Pharmaceuticals US INC | $19.00 | 2023 | Quviviq |
| Mission Pharmacal Company | $13.22 | 2021 | |
| Horizon Therapeutics Plc | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shen-Han Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.